Preservation of Erectile Function after Stereotactic Radiosurgery with CyberKnife for Prostate Cancer
Main Article Content
Abstract
Prostate carcinoma is one of the most significant social oncological diseases among the male population. With the improvement of early diagnosis through PSA screening, new therapeutic options are open to patients. After the introduction of prostatectomy, it was clear the curative treatment for prostate cancer could have unpleasant effect on the erectile function and in this way to worsen the sexual health of men. The alternative of radical surgical treatment is radiotherapy. For that reason, the treatment by Stereotactic Body Radiation Therapy with Cyberknife for low- and intermediate-risk prostate cancer is gaining more and more popularity and scientific evidence. Even that the preservation of the erectile function after prostate radiation is still an ongoing challenge for the modern radiation oncology and the question of how to improve therapeutic techniques to achieve better results remains open
Keywords:
Prostate cancer, CyberKnife, Erectile dysfunction, Erectile function-preserving radiotherapy
Article Details
How to Cite
PAVLOV, Stefan et al.
Preservation of Erectile Function after Stereotactic Radiosurgery with CyberKnife for Prostate Cancer.
Medical Research Archives, [S.l.], v. 11, n. 8, aug. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4294>. Date accessed: 13 may 2024.
doi: https://doi.org/10.18103/mra.v11i8.4294.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Johns Hopkins Hosp. Bull. The early diagnosis and radical cure of carcinoma of the prostate: being a study of 40 cases and presentations of a radical operation which was carried out in 4 cases- 16 (1905), p. 315
2. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insigh t into etiology and prevention. J Urol. 1982;128:492–497. https://doi.org/10.1016/S0022-5347(17)53012-8
3. Kishan AU, King CR. Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. Semin Radiat Oncol. 2017;27:268–78
4. ASTRO: ASTRO Model Policy, 2013
5. Network NCC. NCCN clinical practice guidelines in oncology: prostate cancer (ed Version I.2016). 2015
6. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat. 2003;2(1):25–30
7. Kilby. W. et al. “The CyberKnife Robotic Radiosurgery system in 2010.” TCRT 2010;9(5):433-452
8. Alison C Tree 1, Peter Ostler 2, Hans van der Voet 3, William Chu 4, Andrew Loblaw 4, Daniel et all Ford еt PACE Trial Investigator Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial PMID: 36113498 DOI: 10.1016/S1470-2045(22)00517-
9. Pilepich MV, Krall JM, Sause WT, et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate—analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 351–57.
10. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events v 5.0. Nov 27, 2017. https:// ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ ctcae_v5_quick_reference_5x7.pdf (accessed Sept 1, 2022).
11. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010; 76: 1245–50.
12. Sanda M, Wei JT, Litwin MS. Scoring instructions for the Expanded Prostate cancer Index Composite short form (EPIC-26). 2002. https://medicine.umich.edu/sites/default/files/content/downloads/ Scoring%20Instructions%20for%20the%20EPIC%2026.pdf (accessed Sept 1, 2022).
13. Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology 2015; 85: 101–05
14. ASCO GU 2023: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis
15. Walsh PC, Schlegel PN. Radical pelvic surgery with preservation of sexual function. Ann Surg. 1988;208(4):391–400
16. Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, et al. Potency preservation following stereotactic body radiation therapy for prostate cancer. Radiat Oncol Lond Engl. 2013;8:256
17. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):129–33.
18. Mulhall J, Ahmed A, Parker M, Mohideen N. Original research—erectile dysfunction: the hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med. 2005;2(3):432–7.
19. Johannes CB, Araujo AB, Feldman HA, Derby CA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3
20. Sanda MG, Dunn RL, Michalski J, et al.: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358: 1250-1261. 10.1056/NEJMoa074311
21. King CR, Maxim PG, Hsu A, Kapp DS: Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys 2010, 77: 484-489. 10.1016/j.ijrobp.2009.04.083
22. Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010;76(3):S130-S134. https://doi.org/10.&brea k;1016/j.ijrobp.2009.04.094
23. Murray J, Gulliford S, Griffin C, et al. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. Clin Transl Radiat Oncol. 2020;21:77–84. https://doi.org/10.1016/J.CTRO.2019.12. 006
24. King CR, Lo A, Kapp DS. Testicular dose from prostate CyberKnife: a cautionary note. Int J Radiat Oncol. 2009;73(2):636–7.
25. Lee JY, Spratt DE, Liss AL, McLaughlin PW. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy.Lancet Oncol. 2016;17:e198– e208. https://doi.org/10.1016/S1470-2045(16)00063-2
26. McLaughlin PW, Narayana V, Meriowitz A, et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI? Int J Radiat Oncol Biol Phys. 2005;61:20–31. https://doi.org/10.1016/j.ijrobp.2004.04.070
27. Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59(5):1383–91.
28. Roach M, Faillace-Akazawa P, Malfatti C, Holland J et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35(5):1011–8
2. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insigh t into etiology and prevention. J Urol. 1982;128:492–497. https://doi.org/10.1016/S0022-5347(17)53012-8
3. Kishan AU, King CR. Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. Semin Radiat Oncol. 2017;27:268–78
4. ASTRO: ASTRO Model Policy, 2013
5. Network NCC. NCCN clinical practice guidelines in oncology: prostate cancer (ed Version I.2016). 2015
6. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat. 2003;2(1):25–30
7. Kilby. W. et al. “The CyberKnife Robotic Radiosurgery system in 2010.” TCRT 2010;9(5):433-452
8. Alison C Tree 1, Peter Ostler 2, Hans van der Voet 3, William Chu 4, Andrew Loblaw 4, Daniel et all Ford еt PACE Trial Investigator Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial PMID: 36113498 DOI: 10.1016/S1470-2045(22)00517-
9. Pilepich MV, Krall JM, Sause WT, et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate—analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 351–57.
10. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events v 5.0. Nov 27, 2017. https:// ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ ctcae_v5_quick_reference_5x7.pdf (accessed Sept 1, 2022).
11. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010; 76: 1245–50.
12. Sanda M, Wei JT, Litwin MS. Scoring instructions for the Expanded Prostate cancer Index Composite short form (EPIC-26). 2002. https://medicine.umich.edu/sites/default/files/content/downloads/ Scoring%20Instructions%20for%20the%20EPIC%2026.pdf (accessed Sept 1, 2022).
13. Skolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology 2015; 85: 101–05
14. ASCO GU 2023: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis
15. Walsh PC, Schlegel PN. Radical pelvic surgery with preservation of sexual function. Ann Surg. 1988;208(4):391–400
16. Obayomi-Davies O, Chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, et al. Potency preservation following stereotactic body radiation therapy for prostate cancer. Radiat Oncol Lond Engl. 2013;8:256
17. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;40(1):129–33.
18. Mulhall J, Ahmed A, Parker M, Mohideen N. Original research—erectile dysfunction: the hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med. 2005;2(3):432–7.
19. Johannes CB, Araujo AB, Feldman HA, Derby CA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460–3
20. Sanda MG, Dunn RL, Michalski J, et al.: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358: 1250-1261. 10.1056/NEJMoa074311
21. King CR, Maxim PG, Hsu A, Kapp DS: Incidental testicular irradiation from prostate IMRT: it all adds up. Int J Radiat Oncol Biol Phys 2010, 77: 484-489. 10.1016/j.ijrobp.2009.04.083
22. Roach M, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010;76(3):S130-S134. https://doi.org/10.&brea k;1016/j.ijrobp.2009.04.094
23. Murray J, Gulliford S, Griffin C, et al. Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. Clin Transl Radiat Oncol. 2020;21:77–84. https://doi.org/10.1016/J.CTRO.2019.12. 006
24. King CR, Lo A, Kapp DS. Testicular dose from prostate CyberKnife: a cautionary note. Int J Radiat Oncol. 2009;73(2):636–7.
25. Lee JY, Spratt DE, Liss AL, McLaughlin PW. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy.Lancet Oncol. 2016;17:e198– e208. https://doi.org/10.1016/S1470-2045(16)00063-2
26. McLaughlin PW, Narayana V, Meriowitz A, et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI? Int J Radiat Oncol Biol Phys. 2005;61:20–31. https://doi.org/10.1016/j.ijrobp.2004.04.070
27. Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59(5):1383–91.
28. Roach M, Faillace-Akazawa P, Malfatti C, Holland J et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35(5):1011–8